Jobs
-
The University of Michigan will license an antigen to NanoBio Corporation for development of a nasal vaccine using NanoBio’s NanoStat technology for the prevention of urinary tract infections (UTIs). The antigen works by eliminating E.… Read more . . .
-
Gilead Sciences and MicroDose Therapeutx have reached an agreement for the development and commercialization of MDT-637, a small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV). The dry powder formulation is… Read more . . .
-
NVA237, a once daily, long acting muscarinic agent (LAMA) DPI for the treatment of COPD, met its primary endpoint of improved bronchodilation compared to placebo after 12 weeks. The glycopyrronium bromide dry powder formulation was… Read more . . .
-
European specialty pharma company Axcan will acquire Mpex Pharmaceuticals and its lead candidate, Aeroquin levofloxacin inhalation solution for the treatment of Pseudomonas aeruginosa infections in CF patients, which is currently in Phase 3 trials. Axcan… Read more . . .
-
The FDA has rescheduled its end-of-review meeting with MannKind Corporation regarding Afrezza inhaled insulin for May 4, 2011. The agency had earlier cancelled the meeting, which had been scheduled for April 15, due to a… Read more . . .
-
Dennis Metzger of Albany Medical College (Albany, New York) has presented research at the Society for General Microbiology Spring Conference demonstrating the effectiveness of using interleukin-12 (IL-12) in combination with intranasally-delivered vaccines to boost immune… Read more . . .
-
By mid-2012, Almirall plans to begin clinical studies on a new inhaled drug for the treatment of COPD called LAS190792, the company has announced. The drug is a dry powder formulation of a dual, long-acting… Read more . . .
-
RDD Europe 2011 will be the largest iteration so far of the European version of the Respiratory Drug Delivery meetings, says Richard Dalby of co-organizer RDD. Already, more than 400 people have registered for the… Read more . . .
-
The 2011 IPAC-RS conference, held in Rockville, MD March 29-31, featured speakers from a number of FDA offices discussing the agency’s efforts relevant to orally inhaled and nasal drug products (OINDPs). Among those speakers was… Read more . . .
-
Novartis Canada has announced that it has received a Notice of Compliance from Health Canada for its TOBI Podhaler tobramycin DPI for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients. The product has… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK